223 related articles for article (PubMed ID: 15011165)
1. [New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
Artigas Pallares J
Rev Neurol; 2004 Feb; 38 Suppl 1():S117-23. PubMed ID: 15011165
[TBL] [Abstract][Full Text] [Related]
2. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder].
Velásquez-Tirado JD; Peña JA
Rev Neurol; 2005 Oct 16-31; 41(8):493-500. PubMed ID: 16224736
[TBL] [Abstract][Full Text] [Related]
3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
4. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
[TBL] [Abstract][Full Text] [Related]
6. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
Castellanos FX; Acosta MT
Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598
[TBL] [Abstract][Full Text] [Related]
7. Drugs under investigation for attention-deficit hyperactivity disorder.
Schweitzer JB; Holcomb HH
Curr Opin Investig Drugs; 2002 Aug; 3(8):1207-11. PubMed ID: 12211416
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Prince JB
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
[TBL] [Abstract][Full Text] [Related]
9. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
Shmueli D; Gross-Tsur V
Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157
[TBL] [Abstract][Full Text] [Related]
10. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
[TBL] [Abstract][Full Text] [Related]
11. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
12. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
17. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
19. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
Airaksinen E; Airaksinen MM
Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
[No Abstract] [Full Text] [Related]
20. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
Robison RJ; Reimherr FW; Gale PD; Marchant BK; Williams ED; Soni P; Halls C; Strong RE
Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]